Article
Oncology
Sarah A. Ackroyd, David Arguello, Pilar Ramos, Haider Mahdi, Adam ElNaggar, Ira Winer, Rob Holloway, Thomas Krivak, Nathaniel Jones, Valerie Galvan Turner, Thomas Herzog, Christina Chu, Jubilee Brown, Gina Mantia-Smaldone
Summary: This study analyzed ovarian and endometrial clear cell carcinomas using comprehensive sequencing technology and compared their molecular profiles to clear cell renal cell carcinoma. The results showed that these malignancies have different mutation profiles, but ovarian and endometrial clear cell carcinomas share similar molecular features. The study also suggested that a subset of ovarian clear cell carcinoma may benefit from immunotherapy. Evaluation: 7 out of 10.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Pengfei Cui, Xiaofeng Cong, Youhao Zhang, Huimin Zhang, Ziling Liu
Summary: This study constructed nomograms to predict overall survival (OS) in patients with endometrial clear cell carcinoma (ECCC). The nomograms demonstrated good accuracy, excellent discrimination ability, and clinical benefits, suggesting their potential use in clinical practice.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Vasilios Pergialiotis, Dimitrios Haidopoulos, Theano Christodoulou, Ioannis Rodolakis, Ioannis Prokopakis, Michalis Liontos, Alexandros Rodolakis, Nikolaos Thomakos
Summary: This study evaluated the prognostic factors of disease relapse and overall survival in patients with clear cell carcinoma (CCC) of the endometrium. It found that known predictors of survival rates in endometrioid carcinoma patients had moderate effect on CCC patients, except for the disease stage. Further research is needed to assess whether molecular profiling can help predict survival outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Xinyue Tang, Yuanjing Hu
Summary: Based on TCGA molecular classification, the management and prognosis of CCEC can be improved. Patients with p53abn or NSMP type have a poor prognosis, while those with MMRd or POLEmut type have a favorable prognosis. Adjuvant therapy is recommended for CCEC with p53abn and NSMP, and immune checkpoint inhibitors are beneficial for advanced/recurrent CCEC with MMRd. Further studies are needed to understand the role of molecular classification in CCEC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Xiao-lian Liu, Gui-ming Zhang, Si-si Huang, Wen-hui Shi, Lin-xuan Ye, Zhong-lu Ren, Jia-jie Zhang, Shu-wen Liu, Le Yu, Yi-lei Li
Summary: PTEN loss correlates with hypersensitivity to rapalogs in ccRCC cells and could be a marker for rapalog therapy selection in ccRCC patients.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Pathology
Zeynep Bayramoglu, Sila Yilmaz Erozbek, Isa Aykut Ozdemir, Volkan Ulker, Bahar Muezzinoglu
Summary: High-grade endometrial carcinomas (HGEC) are difficult to classify. In patients with clear cell carcinoma (CCC), HER2 testing can serve as an objective screening method to identify patients who are likely to benefit from HER2-targeted therapy.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Medicine, Research & Experimental
Adam J. Ferrari, Priyanka Rawat, Hannah S. Rendulich, Akshaya Annapragada, Yasuto Kinose, Xiaoming Zhang, Kyle Devins, Anna Budina, Robert B. Scharpf, Marilyn A. Mitchell, Janos L. Tanyi, Mark A. Morgan, Lauren E. Schwartz, T. Rinda Soong, Victor E. Velculescu, Ronny Drapkin
Summary: Epigenetic aberrations, specifically the loss of histone H2B monoubiquitylation (H2Bub1), are associated with the development and progression of clear cell ovarian carcinoma (CCOC). The study identified hypermethylation of RNF40 as a likely mechanism underlying the loss of H2Bub1 in CCOC. Additionally, depletion of H2Bub1 was found to promote cell proliferation and clonogenicity in an endometriosis cell line.
Article
Oncology
Kelly L. Bolton, Denise Chen, Rosario Corona de la Fuente, Zhuxuan Fu, Rajmohan Murali, Martin Kobel, Yanis Tazi, Julie M. Cunningham, Irenaeus C. C. Chan, Brian J. Wiley, Lea A. Moukarzel, Stacey J. Winham, Sebastian M. Armasu, Jenny Lester, Esther Elishaev, Angela Laslavic, Catherine J. Kennedy, Anna Piskorz, Magdalena Sekowska, Alison H. Brand, Yoke-Eng Chiew, Paul Pharoah, Kevin M. Elias, Ronny Drapkin, Michael Churchman, Charlie Gourley, Ann DeFazio, Beth Karlan, James D. Brenton, Britta Weigelt, Michael S. Anglesio, David Huntsman, Simon Gayther, Jason Konner, Francesmary Modugno, Kate Lawrenson, Ellen L. Goode, Elli Papaemmanuil
Summary: This study identifies two distinct molecular subclasses of clear cell ovarian carcinoma (CCOC) with different clinical presentations and outcomes. Tumors with ARID1A mutations are associated with platinum resistance, while tumors with TP53 mutations are associated with extracellular matrix organization and mesenchymal differentiation. TP53-mutated tumors are more likely to be advanced-stage, without a history of endometriosis, and have poorer survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Pathology
Angela Santoro, Antonio Travaglino, Frediano Inzani, Damiano Arciuolo, Giuseppe Angelico, Nicoletta D'Alessandris, Giulia Scaglione, Michele Valente, Maurizio Martini, Antonio Raffone, Gian Franco Zannoni
Summary: The precursors of CC-EC, including CC-EIC, can be diagnosed based on morphological and immunophenotypical features, distinguishing them from metaplastic/reactive changes and their serous counterpart. Despite various putative earlier precursors, there is no clear-cut features for their recognition in common practice, calling for further studies in this field.
DIAGNOSTIC PATHOLOGY
(2021)
Article
Oncology
Shuang Ye, Qin Li, Yutuan Wu, Wei Jiang, Shuling Zhou, Xiaoyan Zhou, Wentao Yang, Xiaoyu Tu, Boer Shan, Shenglin Huang, Huijuan Yang
Summary: We identified an immune subtype of ovarian clear cell carcinoma with poor survival and enrichment of PD-1 and PI3K-AKT-mTOR signaling. We constructed and validated a robust prognostic immune signature for patients with ovarian clear cell carcinoma.
BRITISH JOURNAL OF CANCER
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Murat Yilmaz Kiran, Duygu Has Simsek, Yasemin Sanli, Serkan Kuyumcu
Summary: A 60-year-old woman with clear cell endometrial carcinoma underwent neoadjuvant chemotherapy. Unable to have surgery, the patient was referred to our clinic for disease evaluation. She underwent (18)FDG PET/CT and Ga-68-FAPI-04 PET/CT scans, with Ga-68-FAPI-04 PET/CT outperforming (18)FDG PET/CT in demonstrating higher uptake in metastatic lesions.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Takayuki Mori, Hiroki Kato, Masaya Kawaguchi, Yuichiro Hatano, Takuma Ishihara, Yoshifumi Noda, Fuminori Hyodo, Masayuki Matsuo, Tatsuro Furui, Ken-ichirou Morishige
Summary: This study aimed to evaluate the MRI findings of different types of endometrial cancer. Serous carcinoma (SC) showed heterogeneous signal with peritoneal dissemination and abnormal ascites, while clear cell carcinoma (CCC) exhibited larger tumor size, higher ADC values, infiltrative growth pattern, heterogeneous signal, and abnormal ascites.
EUROPEAN RADIOLOGY
(2022)
Review
Oncology
Amadora Li En Choo, Llewellyn Shao-jen Sim, Kesavan Sittampalam, Wei Chong Tan, Amos Zhi En Tay, Ravichandran Nadarajah, Veronique Kiak Mien Tan, Yirong Sim
Summary: Metastasis of endometrial clear cell carcinoma to the breast is extremely rare. This case report discusses a 70-year-old Chinese woman with metastatic breast lesions mimicking inflammatory breast cancer. The challenges in differentiating primary and metastatic breast lesions are discussed, and the importance of histological features and immunohistochemical staining in diagnosing metastatic breast lesions is emphasized.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ha-Yeon Shin, Wookyeom Yang, Doo Byung Chay, Eun-ju Lee, Joon-Yong Chung, Hyun-Soo Kim, Jae-Hoon Kim
Summary: The study identified TSPAN1 as a key gene in the malignant transformation of endometriosis to ovarian clear cell carcinoma. Upregulation of TSPAN1 enhances cell growth and invasion, potentially serving as a screening candidate for high-risk endometriosis.
MOLECULAR ONCOLOGY
(2021)
Article
Oncology
Jennifer X. Ji, Dawn R. Cochrane, Gian Luca Negri, Shane Colborne, Sandra E. Spencer Miko, Lynn N. Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Kobel, Lucas Feil, Michael Anglesio, Ellen L. Goode, Kelly Bolton, Gregg B. Morin, David G. Huntsman
Summary: Clear cell ovarian carcinoma (CCOC) has distinct proteomic differences compared with other subtypes of epithelial ovarian carcinoma, and potentially significant proteomic subgroups within CCOC, suggesting the possibility of stratified treatment for this cancer.
JOURNAL OF PATHOLOGY
(2022)
Article
Obstetrics & Gynecology
Linyuan Wang, Anna Piskorz, Tjalling Bosse, Mercedes Jimenez-Linan, Brian Rous, C. Blake Gilks, James D. Brenton, Naveena Singh, Martin Kobel
Summary: PTEN plays a central role in the pathogenesis of endometrial carcinoma. PTEN IHC shows moderate accuracy in predicting loss of function PTEN mutations, and can be used for diagnostic purposes.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Obstetrics & Gynecology
Varsha Shah, Sian E. Morgan, Martin Kobel, Cheng-Han Lee, W. Glenn McCluggage
Summary: Breast metastasis from endometrial carcinoma is extremely rare, and dedifferentiation in the metastatic site is even rarer. This case report highlights the importance of recognizing this phenomenon to avoid misdiagnosis.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Obstetrics & Gynecology
Katharina Wiedemeyer, Linyuan Wang, Eun Young Kang, Shuhong Liu, Young Ou, Linda E. Kelemen, Lukas Feil, Michael S. Anglesio, Sarah Glaze, Prafull Ghatage, Gregg S. Nelson, Martin Koebel
Summary: This study aimed to test prognostic biomarkers in patients with stage I ovarian clear cell carcinoma (OCCC) and to survey the expression of actionable targets in stage II to IV cases. The combination of p53, p16, and IGF2BP3 was proposed as a predictor of prognosis and potential need for adjuvant therapy in stage I OCCC patients.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2022)
Article
Oncology
Jeffrey Boschman, Hossein Farahani, Amirali Darbandsari, Pouya Ahmadvand, Ashley Van Spankeren, David Farnell, Adrian B. Levine, Julia R. Naso, Andrew Churg, Steven J. M. Jones, Stephen Yip, Martin Kobel, David G. Huntsman, C. Blake Gilks, Ali Bashashati
Summary: This study compared eight color normalization algorithms for AI-based classification of H&E-stained histopathology slides, finding that while color normalization does not consistently improve classification on single-center data, it significantly enhances accuracy on multi-center datasets. Introducing a novel augmentation strategy by mixing color-normalized images using three algorithms consistently improves diagnosis of test images from external centers, showing the potential for reliable color normalization in AI-based digital pathology diagnosis of cancers from multiple centers.
JOURNAL OF PATHOLOGY
(2022)
Review
Oncology
Martin Kobel, Eun Young Kang
Summary: Research has shown that ovarian carcinomas consist of multiple distinct histologic types and molecular subtypes, representing different diseases. By grouping tumors based on molecular similarities, research and future patient management can be facilitated. Utilizing immunohistochemical markers and histotype-specific oncogenic alterations can confirm morphological diagnoses for different histotypes.
Article
Pathology
Eun Young Kang, Nicholas J. P. Wiebe, Christa Aubrey, Cheng-Han Lee, Michael S. Anglesio, Derek Tilley, Prafull Ghatage, Gregg S. Nelson, Sandra Lee, Martin Kobel
Summary: The study aimed to test the sensitivity of tumor morphology in capturing p53 abnormal cases and model the impact of p53 abnormality on ESGO risk stratification. The results showed that predicting p53 abnormality using nuclear features is accurate, and in a small percentage of cases, p53 abnormality can lead to changes in ESGO risk group classification.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2022)
Article
Pathology
Felix K. F. Kommoss, Sarah Chiang, Martin Kobel, Christian Koelsche, Kenneth Tou-En Chang, Julie A. Irving, Brendan Dickson, Sakinah Thiryayi, Marjan Rouzbahman, Golnar Rasty, Andreas von Deimling, Cheng-Han Lee, Gulisa Turashvili
Summary: The study aims to clarify the classification of endometrial stromal sarcomas (ESS) with variant alterations involving BCOR or BCORL1 by describing their clinicopathologic and molecular features. The results indicate that ESS with BCOR internal tandem duplication and variant BCOR and BCORL1 rearrangements clinically and molecularly resemble conventional high-grade endometrial stromal sarcomas.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Article
Cell Biology
Basile Tessier-Cloutier, Eun-Young Kang, Deepu Alex, Colin J. R. Stewart, W. Glenn McCluggage, Martin Kobel, Cheng-Han Lee
Summary: This study found that neuroendocrine marker expression in SWI/SNF-deficient DDECs/UDECs is typically focal, while NECs typically express two or more neuroendocrine markers. Immunohistochemistry can be used to differentiate between DDEC/UDEC and NEC.
Article
Oncology
Felix K. F. Kommoss, Basile Tessier-Cloutier, Leora Witkowski, Erna Forgo, Christian Koelsche, Martin Kobel, William D. Foulkes, Cheng-Han Lee, David L. Kolin, Andreas von Deimling, Brooke E. Howitt
Summary: SWI/SNF complex deficiency is common in various cancers, especially in the gynecologic tract. Despite their similar morphology, UDEC, SDUS, and SCCOHT have distinct DNA methylation signatures. Our study highlights the importance of cellular context in determining the epigenetic landscape and suggests that methylation profiling may be a useful diagnostic tool in undifferentiated, SWI/SNF-deficient cancers.
JOURNAL OF PATHOLOGY
(2022)
Article
Oncology
Kelly L. Bolton, Denise Chen, Rosario Corona de la Fuente, Zhuxuan Fu, Rajmohan Murali, Martin Kobel, Yanis Tazi, Julie M. Cunningham, Irenaeus C. C. Chan, Brian J. Wiley, Lea A. Moukarzel, Stacey J. Winham, Sebastian M. Armasu, Jenny Lester, Esther Elishaev, Angela Laslavic, Catherine J. Kennedy, Anna Piskorz, Magdalena Sekowska, Alison H. Brand, Yoke-Eng Chiew, Paul Pharoah, Kevin M. Elias, Ronny Drapkin, Michael Churchman, Charlie Gourley, Ann DeFazio, Beth Karlan, James D. Brenton, Britta Weigelt, Michael S. Anglesio, David Huntsman, Simon Gayther, Jason Konner, Francesmary Modugno, Kate Lawrenson, Ellen L. Goode, Elli Papaemmanuil
Summary: This study identifies two distinct molecular subclasses of clear cell ovarian carcinoma (CCOC) with different clinical presentations and outcomes. Tumors with ARID1A mutations are associated with platinum resistance, while tumors with TP53 mutations are associated with extracellular matrix organization and mesenchymal differentiation. TP53-mutated tumors are more likely to be advanced-stage, without a history of endometriosis, and have poorer survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Obstetrics & Gynecology
Teresa H. Praetorius, Anna Leonova, Vivian Lac, Janine Senz, Basile Tessier-Cloutier, Tayyebeh M. Nazeran, Martin Kobel, Marcel Grube, Bernhard Kraemer, Paul J. Yong, Stefan Kommoss, Michael S. Anglesio
Summary: This study investigated the heterogeneity of somatic cancer-driver mutations within patients and across different types of endometriosis. The results showed that identical mutations were found across distinct lesions, indicating clonality in endometriosis. Additionally, endometriomas exhibited higher mutational complexity, with functionally redundant driver mutations within the same gene. The study suggests that the current anatomically defined classification of endometriosis does not fully recognize the etiology of the disease, and a novel classification considering genomic and other molecular features should be considered.
FERTILITY AND STERILITY
(2022)
Article
Oncology
Dane Cheasley, Marta Llaurado Fernandez, Martin Kobel, Hannah Kim, Amy Dawson, Joshua Hoenisch, Madison Bittner, Derek S. Chiu, Aline Talhouk, C. Blake Gilks, Madawa W. Jayawardana, Kathleen Pishas, Anne-Marie Mes-Masson, Diane Provencher, Abhimanyu Nigam, Neville F. Hacker, Kylie L. Gorringe, Ian G. Campbell, Mark S. Carey
Summary: This study investigates the genomic profiles associated with estrogen receptor (ER) and progesterone receptor (PR) expression patterns in low-grade serous ovarian carcinoma (LGSOC). The results show that PR-low tumors have a higher fraction of the genome altered by copy number changes compared to PR-high tumors. Higher expression of ER and PR is associated with improved overall survival.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Jennifer X. Ji, Dawn R. Cochrane, Gian Luca Negri, Shane Colborne, Sandra E. Spencer Miko, Lynn N. Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Kobel, Lucas Feil, Michael Anglesio, Ellen L. Goode, Kelly Bolton, Gregg B. Morin, David G. Huntsman
Summary: Clear cell ovarian carcinoma (CCOC) has distinct proteomic differences compared with other subtypes of epithelial ovarian carcinoma, and potentially significant proteomic subgroups within CCOC, suggesting the possibility of stratified treatment for this cancer.
JOURNAL OF PATHOLOGY
(2022)
Article
Pathology
Hossein Farahani, Jeffrey Boschman, David Farnell, Amirali Darbandsari, Allen Zhang, Pouya Ahmadvand, Steven J. M. Jones, David Huntsman, Martin Kobel, C. Blake Gilks, Naveena Singh, Ali Bashashati
Summary: Machine learning algorithms can assist pathologists in diagnosing ovarian carcinoma histotype, potentially improving diagnostic performance.
Article
Anatomy & Morphology
Maire A. Duggan, Qiuli Duan, Ruth M. Pfeiffer, Mary Anne Brett, Sandra Lee, Mustapha Abubakar, Martin Kobel, Monica Rodriguez, Aylin Sar
Summary: This study aimed to compare the diagnoses of the International Endocervical adenocarcinoma Criteria and Classification (IECC) algorithm with H&E-based IECC histotyping and validated the use of random forest (RF) classification for more accurate discrimination. The results showed that the IECC algorithm performed poorly in histotyping, while the RF algorithm showed favorable results in distinguishing between HPVA and NHPV.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2022)